Inhibition or deletion of MAGL has therapeutic effects in animal models of Parkinson’s disease [14] and Alzheimer’s disease [32] by blocking AA and PG production, but not by cannabinoid-receptor-mediated signaling. This evidence concerns the gene MGLL and Alzheimer disease.